{"id":390238,"date":"2020-04-22T00:00:00","date_gmt":"2020-04-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2020-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2020\/"},"modified":"2026-04-18T11:36:19","modified_gmt":"2026-04-18T11:36:19","slug":"algoim0057-2020-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2020-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2020\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2020"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation-predominant, diarrhea-predominant (IBS-D), and mixed. This analysis focuses on IBS-D. Treatment options for IBS are limited, and only a few drugs have secured FDA approval for IBS-D. Current options include Sebela Pharmaceuticals\u2019 Lotronex, Salix Pharmaceuticals\u2019 Xifaxan, Allergan\u2019s Viberzi, and off-label use of antidepressants, motor stimulants, and anticholinergic agents.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?<\/li>\n<li>How have Xifaxan and Viberzi been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li>What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?<\/li>\n<li>What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p>Geography: United States<\/p>\n<p>Key drugs covered: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate \/ scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate<\/p>\n","protected":false},"template":"","class_list":["post-390238","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390238\/revisions"}],"predecessor-version":[{"id":393363,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390238\/revisions\/393363"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}